PREVENTIVE EFFECT OF PIRFENIDONE AGAINST EXPERIMENTAL SCLEROSING PERITONITIS IN RATS
PREVENTIVE EFFECT OF PIRFENIDONE AGAINST EXPERIMENTAL SCLEROSING PERITONITIS IN RATS
复制标题
DOI：
10.1016/s0940-2993(11)80261-7
复制
发表时间：
1995-09-01
影响因子：
--
通讯作者：
MARGOLIN, SB
中科院分区：
文献类型：
--
作者：
HIDEIKU, S;TERAOKA, S;MARGOLIN, SB
本文观察了新开发的抗纤维化药物吡非尼酮(PFD)对大鼠实验性硬化性腹膜炎(SP)的预防作用。雄性Wistar大鼠(体重150-250g)随机分为两组，每组7只。将0.1%葡萄糖酸氯己定(CH)和15%乙醇加入2ml生理盐水中注射，连续26天作为SP模型对照组(CH组)，6只大鼠每日灌胃(P.O.)在每日ipp的基础上加用350 mg/kg的PFD。注射上述CH-乙醇-生理盐水26d(CH+PFD组)。对腹膜内大体改变和组织学纤维化改变进行盲法评分，光镜下观察测量浆膜下实际厚度。CH+PFD组体重增长显著高于CH组(P<；0.05)。CH+PFD组大体腹膜粘连改变明显少于CH组(P<；0.05)。CH+PFD组肝、肠的纤维化改变较少，浆膜下厚度较小，差异有统计学意义(P<；0.1)。结论：PFD对CH诱导的实验性硬化性腹膜炎有明显的抑制或预防作用。
We investigated the preventive effect of pirfenidone (PFD), a newly developed anti-fibrotic agent, on experimental sclerosing peritonitis (sp) which we had established in rats. Male Wistar rats (150-250 g) were divided into the following two groups; 7 rats were treated with daily intraperitoneal (i.p.) injection of 0.1% chlorhexidine gluconate (CH) and 15% ethanol solved in 2 ml of saline for 26 days as a control of SP model (CH group) and 6 rats were treated daily with peroral (p.o.) administration of 350 mg/kg of PFD in addition to the daily i.p. injection of aforementioned CH-ethanol-saline solution for 26 days (CH + PFD group). Macroscopic intraperitoneal changes and histological fibrotic changes were graded by scoring in a blind manner.Actual subserosal thickness was measured by observation under light microscope. Body weight gain was significantly greater in CH + PFD group than in CH group (P < 0.05). Macroscopic intraperitoneal adhesion changes in CH + PFD group were significantly fewer than in CH group (P < 0.05). Fibrotic changes were fewer and subserosal thickness in liver and intestine were smaller in CH + PFD group with statistical significance (p < 0.1).We concluded that PFD markedly inhibited or prevented fibrotic changes in the experimental sclerosing peritonitis induced by CH.